We are live on
!
Find out more
Mirae Asset Global Investments Portfolio holdings
AUM
$67.7B
1-Year Est. Return
57.61%
This Fund
S&P 500
This Quarter
Est. Return
+4.4%
1 Year Est. Return
+57.61%
3 Year Est. Return
+150.9%
5 Year Est. Return
+201.56%
10 Year Est. Return
+1,018.7%
AUM
$24.6B
AUM Growth
+$2.03B
(+9%)
Cap. Flow
+$1.28B
Cap. Flow
% of AUM
5.2%
Top 10 Holdings %
Top 10 Hldgs %
38.38%
Holding
1,702
New
151
Increased
731
Reduced
674
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$167M |
| 2 |
Apple
AAPL
|
+$66M |
| 3 |
Microsoft
MSFT
|
+$57.3M |
| 4 |
HDFC Bank
HDB
|
+$44M |
| 5 |
Schwab US Dividend Equity ETF
SCHD
|
+$41.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$81.5M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$81.3M |
| 3 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$45.8M |
| 4 |
Advanced Micro Devices
AMD
|
+$43.4M |
| 5 |
Meta Platforms (Facebook)
META
|
+$35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.15% |
| 2 | Consumer Discretionary | 10.25% |
| 3 | Communication Services | 8.94% |
| 4 | Healthcare | 6.61% |
| 5 | Financials | 5.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
MeiraGTx Holdings
MGTX
$1.17B
| $16.2K | ﹤0.01% |
2,604
-195
| -7% | -$1.14K |
|
1452
Theravance Biopharma
TBPH
$878M
| $15.7K | ﹤0.01% |
1,639
-130
| -7% | -$1.18K |
|
1453
Alpha Teknova
TKNO
$396M
| $15.5K | ﹤0.01% |
+1,776
| New | +$12.4K |
|
1454
Sprott Uranium Miners ETF
URNM
$2B
| $15.5K | ﹤0.01% |
387
| – | – |
|
1455
IPG Photonics
IPGP
$3.57B
| $15.4K | ﹤0.01% |
210
-53
| -20% | -$4.07K |
|
|
THRD
1456
DELISTED
Third Harmonic Bio
THRD
| $15.4K | ﹤0.01% |
1,502
+16
| +1% | +$199 |
|
1457
Arcturus Therapeutics
ARCT
$223M
| $15.4K | ﹤0.01% |
903
-75
| -8% | -$1.41K |
|
1458
Allogene Therapeutics
ALLO
$683M
| $15.3K | ﹤0.01% |
6,987
-576
| -8% | -$1.42K |
|
1459
UroGen Pharma
URGN
$2.34B
| $15.1K | ﹤0.01% |
1,406
-117
| -8% | -$1.4K |
|
|
AUTL
1460
Autolus Therapeutics
AUTL
$591M
| $15K | ﹤0.01% |
6,655
-565
| -8% | -$1.91K |
|
|
ESPR
1461
DELISTED
Esperion Therapeutics
ESPR
| $15K | ﹤0.01% |
+6,566
| New | +$15.3K |
|
1462
Zevra Therapeutics
ZVRA
$664M
| $14.9K | ﹤0.01% |
+1,779
| New | +$15.2K |
|
|
FPI
1463
Farmland Partners
FPI
$425M
| $14.8K | ﹤0.01% |
1,277
-499
| -28% | -$5.86K |
|
1464
HUTCHMED
HCM
$2.11B
| $14.8K | ﹤0.01% |
1,034
-88
| -8% | -$1.57K |
|
1465
Steven Madden
SHOO
$3.46B
| $14.7K | ﹤0.01% |
+347
| New | +$15.6K |
|
1466
MaxCyte
MXCT
$149M
| $14.5K | ﹤0.01% |
3,515
-286
| -8% | -$1.08K |
|
1467
OmniAb
OABI
$499M
| $14.5K | ﹤0.01% |
4,033
-241
| -6% | -$953 |
|
1468
Monte Rosa Therapeutics
GLUE
$1.35B
| $14.5K | ﹤0.01% |
+2,047
| New | +$15.4K |
|
|
CHCT
1469
Community Healthcare Trust
CHCT
$433M
| $14.4K | ﹤0.01% |
783
-292
| -27% | -$5.29K |
|
|
DDL
1470
Dingdong
DDL
$512M
| $14.3K | ﹤0.01% |
+3,986
| New | +$15.4K |
|
1471
Phibro Animal Health
PAHC
$1.38B
| $14.3K | ﹤0.01% |
678
-58
| -8% | -$1.34K |
|
|
BFS
1472
Saul Centers
BFS
$865M
| $14.2K | ﹤0.01% |
370
-142
| -28% | -$5.69K |
|
1473
SIGA Technologies
SIGA
$207M
| $14.1K | ﹤0.01% |
2,379
-202
| -8% | -$1.35K |
|
1474
Aura Biosciences
AURA
$791M
| $13.9K | ﹤0.01% |
+1,665
| New | +$15.7K |
|
|
KALV
1475
DELISTED
KalVista Pharmaceuticals
KALV
| $13.8K | ﹤0.01% |
1,623
+65
| +4% | +$673 |
|
Similar funds
BC
Mirae Asset Global Investments's Q4 2024 Portfolio in Review
As of Q4 2024, Mirae Asset Global Investments held 1,702 positions worth $24.6B, up 9% from $22.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Mirae Asset Global Investments deployed $1.28B of net new capital in Q4 2024, opening 151 new positions and adding to 731 existing holdings. Its largest new stake was Strategy Inc: 36,162 shares worth $11.8M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Consumer Discretionary and Communication Services.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $81.5M trimmed.
- Mirae Asset Global Investments's largest Q4 2024 buy was Strategy Inc: 36,162 shares worth $11.8M.
- Mirae Asset Global Investments added most to Vanguard S&P 500 ETF in Q4 2024, an estimated $167M increase.
- Mirae Asset Global Investments's biggest Q4 2024 reduction was Invesco QQQ Trust, cutting an estimated $81.5M.
- Mirae Asset Global Investments fully exited VanEck Pharmaceutical ETF in Q4 2024, selling an estimated $23.6M.
- Mirae Asset Global Investments's ten largest holdings make up 38% of its $24.6B portfolio in Q4 2024.
- Mirae Asset Global Investments opened 151 new positions and closed 110 in Q4 2024.
- Mirae Asset Global Investments's portfolio value rose 9% quarter-over-quarter to $24.6B.
Based on Mirae Asset Global Investments's 13F filing for Q4 2024, filed 27 Jan 2025.